Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trickle Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (814)	8/30/2001 1:51:18 AM
From: tuck	Read Replies (2) \| Respond to of 1784

Hey, Nigel, Nice suggestion of DCGN for T/FIF. Care to risk your track record over here? Anyhow, back to newshounding . . . A few days ago I was taking a casual bike ride west of my Mira Mesa neighborhood and decided to check out all the high tech buildings around, one of which is occupied by NGEN (which I own a little of -- waiting for Godot), others by ELAN & DVSA, and a small but slick looking one occupied by these folks . . . >>SAN DIEGO--(BW HealthWire)--Aug. 29, 2001--Gene Therapy Systems Inc., a provider of advanced delivery tools and platform technologies for the biotechnology industry, today announced that the United States Patent Offices has awarded the company a new patent (6,280,977) covering the method for generating transcriptionally active DNA fragments using the polymerase chain reaction (PCR). GTS' Transcriptionally Active PCR (TAP) technology greatly accelerates the speed of going from gene to protein by eliminating cloning bottlenecks such as restriction enzyme digestion, ligation, bacterial transformation and plasmid preparation. The TAP technology is particularly powerful when a large number of genes need to be simultaneously generated in a transcriptionally active form. GTS is currently utilizing the TAP technology to be the leader in generating the first complete human proteome as well as other microbial proteomes involved in human diseases. The vast amount of information made available by the genomics efforts is rapidly shifting the focus of today's research towards elucidating the function of proteins in the human body. Traditionally, expressing proteins from DNA involves the time-consuming process of cloning a DNA fragment into an expression vector, purifying and propagating the vector, and eventually delivering the vector into a host for expression. The GTS patented TAP technology allows researchers to generate DNA fragments that are expression ready in two simple PCR steps. The TAP fragments, which include a promoter/enhancer sequence, the gene of interest and a terminator sequence, can be used directly for high-level expression in living cells in vitro or injected into animal for in vivo studies. GTS provides several research kits based on the TAP technology through its product catalog and worldwide network of distributors. ``Our aim is to help pharmaceutical scientists to fully benefit from the vast amount of genomics information in their functional screening studies,'' said Anthony Sorge, chief executive officer of GTS. ``We are very excited about our TAP technology and believe strongly in its potential in the proteomics and vaccinomics areas.'' The company is also seeking strategic partners that can benefit from the TAP technology in their target validation and drug development programs. Gene Therapy Systems Inc. is a privately held biotechnology company, incorporated in Delaware in 1998 and located in San Diego. GTS specializes in the development and acquisition of novel platform technologies that can be used for therapeutic applications, especially ones that increase the bioavailability of genes and proteins in live cells. The company is building a robust intellectual property portfolio that is leveraged in its research reagent business and in pharmaceutical licensing and research collaborations.<< snip Don't know if they'll be sufficiently tricklish if and when they go public, but major improvements on PCR are something Trickle likes to keep an eye on. Cheers, Tuck